Frankfurt - Delayed Quote EUR

Bavarian Nordic A/S (BV3.F)

21.92
+0.37
+(1.72%)
At close: May 16 at 9:39:12 PM GMT+2
Loading Chart for BV3.F
  • Previous Close 21.55
  • Open 21.57
  • Bid 21.90 x 10000
  • Ask 22.34 x 10000
  • Day's Range 21.57 - 22.11
  • 52 Week Range 17.81 - 42.70
  • Volume 90
  • Avg. Volume 651
  • Market Cap (intraday) 1.734B
  • Beta (5Y Monthly) 1.21
  • PE Ratio (TTM) 9.74
  • EPS (TTM) 2.25
  • Earnings Date May 9, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

www.bavarian-nordic.com

1,645

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BV3.F

View More

Performance Overview: BV3.F

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .

YTD Return

BV3.F
13.94%
OMX Copenhagen 25 Index (^OMXC25)
5.18%

1-Year Return

BV3.F
5.19%
OMX Copenhagen 25 Index (^OMXC25)
15.07%

3-Year Return

BV3.F
22.08%
OMX Copenhagen 25 Index (^OMXC25)
0.00%

5-Year Return

BV3.F
15.82%
OMX Copenhagen 25 Index (^OMXC25)
35.60%

Compare To: BV3.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BV3.F

View More

Valuation Measures

As of 5/15/2025
  • Market Cap

    1.70B

  • Enterprise Value

    1.55B

  • Trailing P/E

    9.57

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.05

  • Price/Book (mrq)

    1.08

  • Enterprise Value/Revenue

    1.86

  • Enterprise Value/EBITDA

    5.76

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    21.20%

  • Return on Assets (ttm)

    6.65%

  • Return on Equity (ttm)

    12.16%

  • Revenue (ttm)

    6.23B

  • Net Income Avi to Common (ttm)

    1.32B

  • Diluted EPS (ttm)

    2.25

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.24B

  • Total Debt/Equity (mrq)

    1.01%

  • Levered Free Cash Flow (ttm)

    -2.87B

Research Analysis: BV3.F

View More

People Also Watch